Zhang Fu, Hu Qida, Li Bowen, Huang Yong, Wang Meng, Shao Shiyi, Tang Honglin, Yao Zhuo, Ping Yuan, Liang Tingbo
Department of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou 310003, China; College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
Department of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou 310003, China.
J Control Release. 2023 Feb;354:835-850. doi: 10.1016/j.jconrel.2023.01.007. Epub 2023 Jan 30.
Pancreatic ductal adenocarcinoma (PDAC) remains to be one of the highest malignant tumors due to its poor chemotherapeutic efficacy and multidrug resistance. A major reason for the failure in chemotherapy is poor drug accumulation into PDAC tumor tissues due to the overexpressed extracellular matrix (ECM) stroma, which forms a major obstacle limiting the deep tissue penetration of chemotherapeutics. Herein, we report a tumor microenvironment (TME)-responsive nanodrug, based on PDAC cell membrane-coated gold nanocages (AuNCs), to co-deliver the chemotherapeutics (GEM) and nitrogen oxide (NO) donor (L-Arg) to enhance drug accumulation and reduce chemoresistance. The high glutathione (GSH) level can trigger the cleavage of the disulfide bond on nanodrug to release GEM. Moreover, the elevated ROS level could activate L-Arg to generate NO, which synergistically facilitate GEM to penetrate into deep tissues by means of vasodilation and normalization of blood vessels in the PDAC tumor tissue. In addition, AuNCs not only serve as a photothermal agent for chemotherapy, but also generate photoacoustic signals to monitor drug accumulation and distribution. As expected, the strategy demonstrates to be remarkable in treating different xenograft mice models, especially in orthotopic and patient-derived xenograft (PDX) models. The current study defines a useful therapeutic tool for treating PDAC tumors.
胰腺导管腺癌(PDAC)由于其化疗疗效差和多药耐药性,仍然是恶性程度最高的肿瘤之一。化疗失败的一个主要原因是由于细胞外基质(ECM)基质过度表达,化疗药物在PDAC肿瘤组织中的蓄积不良,这形成了限制化疗药物深入组织渗透的主要障碍。在此,我们报告一种基于PDAC细胞膜包被金纳米笼(AuNCs)的肿瘤微环境(TME)响应性纳米药物,用于共递送化疗药物(吉西他滨,GEM)和一氧化氮(NO)供体(L-精氨酸,L-Arg),以增强药物蓄积并降低化疗耐药性。高谷胱甘肽(GSH)水平可触发纳米药物上二硫键的断裂以释放GEM。此外,升高的活性氧(ROS)水平可激活L-Arg生成NO,通过血管舒张和使PDAC肿瘤组织中的血管正常化,协同促进GEM渗透到深部组织中。此外,AuNCs不仅作为化疗的光热剂,还产生光声信号以监测药物的蓄积和分布。正如预期的那样,该策略在治疗不同的异种移植小鼠模型中表现出色,尤其是在原位和患者来源的异种移植(PDX)模型中。当前的研究定义了一种治疗PDAC肿瘤的有用治疗工具。